Amgen vs Radius: Who Will Dominate Bone Density Market?

The market for osteoporosis drugs is heating up. Radius Health (RDUS) unveiled strong clinical trial data for its once-daily bone formation drug abaloparatide, a rival to Eli Lilly’s (LLY) Forteo. Next year, biotech giant Amgen (AMGN) is slated to disclose results from a phase 3 study for its drug romosozumab. But according to Deutsche Bank […]